Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

46.41USD
16 Aug 2017
Change (% chg)

$0.90 (+1.98%)
Prev Close
$45.51
Open
$44.92
Day's High
$46.86
Day's Low
$44.60
Volume
4,033,322
Avg. Vol
2,001,709
52-wk High
$47.98
52-wk Low
$30.89

NVO

Chart for NVO

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.61
Market Cap(Mil.): $89,503.08
Shares Outstanding(Mil.): 1,962.56
Dividend: 0.47
Yield (%): 2.08

Financials

  NVO Industry Sector
P/E (TTM): 18.66 31.12 32.38
EPS (TTM): 2.43 -- --
ROI: 76.65 15.33 14.90
ROE: 84.84 16.36 16.15

Novo Nordisk's diabetes drug succeeds in key trial

Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

6:45pm EDT

UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

6:36pm EDT

Novo Nordisk's diabetes drug succeeds in key trial

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

5:31pm EDT

BRIEF-Novo Nordisk says Semaglutide superior to Dulaglutide in sustain 7 trial

* Novo nordisk says semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in sustain 7

2:17pm EDT

BRIEF-‍Metacrine enters collaboration with Novo Nordisk to develop FGF 1 variants for glucose lowering, insulin sensitization​

* ‍Metacrine - entered collaboration with Novo Nordisk A/S to develop fibroblast growth factor 1 variants for glucose lowering and insulin sensitization​

Aug 15 2017

UPDATE 1-European shares fall on Paris incident, North Korea worries

* Overall euro zone Q2 earnings growth tracking 16 pct (Recasts, adds detail and quote, updates prices at close)

Aug 09 2017

UPDATE 2-Novo Nordisk raises forecasts despite continued U.S. pressure

* Shares jump more than 6 percent (Adds management comments, obesity drugs background, shares)

Aug 09 2017

BRIEF-Novo Nordisk CEO says won't provide explicit guidance on price

* CEO SAYS NOVO NORDISK DO NOT INTEND TO PROVIDE EXPLICIT GUIDANCE ON PRICE IN THE FUTURE

Aug 09 2017

NORDIC STOCKS - Factors to watch on August 9

OSLO, Aug 9 The following stocks may be affected by newspaper reports and other factors on Wednesday:

Aug 09 2017

Novo Nordisk Q2 beats forecast; lifts outlook but sees lower U.S. prices in 2018

COPENHAGEN, Aug 9 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, posted second-quarter operating profit above forecasts, but said prices in its key U.S. market after rebates would be lower next year.

Aug 09 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €82.58 --
Eli Lilly and Co (LLY.N) $80.69 -1.02

Earnings vs. Estimates